A Combination of Senna Leaf Extract, Prune Fibre and Inulin Relieves Opioid-Induced Constipation and Regulates Gut Microbiota in Cancer Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
DOI:
https://doi.org/10.5281/zenodo.22343811Keywords:
opioid-induced constipation, senna, prune fibre, inulin, gut microbiotaAbstract
Background: Opioid-induced constipation (OIC) affects most cancer patients on chronic opioid therapy and is frequently
under-treated. Objective: To synthesise published evidence on senna, prune fibre and inulin, alone and combined, for OIC and gut
microbiota modulation in cancer/palliative populations. Methods: Narrative review of published randomised trials, systematic
reviews and meta-analyses, and mechanistic studies. Findings: Stimulant laxatives, bulking fruit fibre and prebiotic fructans each
improve stool frequency and consistency, and prebiotic fibre additionally enriches saccharolytic taxa and short-chain fatty acid
output, supporting rationale for combined use. Conclusions: A multimodal senna-prune fibre-inulin regimen is mechanistically
plausible and merits dedicated trials in opioid-treated cancer patients.
References
Davies A, Leach C, Butler C, et al. Opioid-induced constipation in patients with cancer: a "real-world," multicentre, observational study of diagnostic criteria and clinical features. Pain. 2021;162(1):309-318. doi:10.1097/j.pain.0000000000002024
Abramowitz L, Beziaud N, Labreze L, et al. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain. Int J Clin Pract. 2013;67(11):1054-1064. doi:10.1111/ijcp.12194
Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014;26(10):1386-1395. doi:10.1111/nmo.12417
Farmer AD, Drewes AM, Chiarioni G, et al. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. United European Gastroenterol J. 2019;7(1):7-20. doi:10.1177/2050640618818305
Droney J, Ross J, Gretton S, Welsh K, Sato H, Riley J. Constipation in cancer patients on morphine. Support Care Cancer. 2008;16(5):453-459. doi:10.1007/s00520-007-0313-0
LoCasale RJ, Datto CJ, Margolis MK, Coyne KS. Impact and consequences of opioid-induced constipation: a survey of patients. Pain Ther. 2021;10(2):1253-1266. doi:10.1007/s40122-021-00284-9
Larkin PJ, Cherny NI, La Carpia D, et al. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv111-iv125. doi:10.1093/annonc/mdy148
Larkin PJ, Sykes NP, Centeno C, et al. The management of constipation in palliative care: clinical practice recommendations. Palliat Med. 2008;22(7):796-807. doi:10.1177/0269216308096908
Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S. American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation. Gastroenterology. 2019;156(1):218-226. doi:10.1053/j.gastro.2018.07.016
Luthra P, Burr NE, Brenner DM, Ford AC. Efficacy of naldemedine for the treatment of opioid-induced constipation: a systematic review and meta-analysis. Gut. 2019;68(3):434-444. doi:10.1136/gutjnl-2018-316001
Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2016;44(7):693-703. doi:10.1111/apt.13746
Acharya C, Fagan A, Bajaj JS, et al. Opioid use and gut dysbiosis in cancer pain patients. Sci Rep. 2024;14:17287. doi:10.1038/s41598-024-67432-2
Wang J, Liu YQ, Hou WJ, et al. Pharmacology, toxicology, and metabolism of sennoside A, a medicinal plant-derived natural compound. Front Pharmacol. 2021;12:714586. doi:10.3389/fphar.2021.714586
Jansen A, Berkius J, Herdes O, et al. Senna versus magnesium oxide for the treatment of chronic constipation: a randomized, placebo-controlled trial. Am J Gastroenterol. 2020;115(12):2029-2036. doi:10.14309/ajg.0000000000000942
Rana SV, Bhardwaj SB. Efficacy of lactulose versus senna plus ispaghula husk among patients with pre-dialysis chronic kidney disease and constipation: a randomized controlled trial. Cureus. 2021;13(7):e16612. doi:10.7759/cureus.16612
Liu Z, Peng L, Guo B, et al. Review on melanosis coli and anthraquinone-containing traditional Chinese herbs that cause melanosis coli. Front Pharmacol. 2023;14:1160480. doi:10.3389/fphar.2023.1160480
Attaluri A, Donahoe R, Valestin J, Brown K, Rao SS. Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation. Aliment Pharmacol Ther. 2011;33(7):822-828. doi:10.1111/j.1365-2036.2011.04594.x
Lever E, Cole J, Scott SM, Emery PW, Whelan K. Systematic review: the effect of prunes on gastrointestinal function. Aliment Pharmacol Ther. 2014;40(7):750-758. doi:10.1111/apt.12913
Lever E, Scott SM, Louis P, Emery PW, Whelan K. The effect of prunes on stool output, gut transit time and gastrointestinal microbiota: a randomised controlled trial. Clin Nutr. 2019;38(1):165-173. doi:10.1016/j.clnu.2018.01.003
Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne). 2020;11:25. doi:10.3389/fendo.2020.00025
Pedersen SS, Prause M, Williams AR, Krych L, Nielsen DS, Kot W, et al. Inulin-induced improvements on bowel habit and gut microbiota in adults with functional constipation: findings of a randomized, double-blind, placebo-controlled study. BMC Gastroenterol. 2025;25:611. doi:10.1186/s12876-025-04409-6
Zhu L, Liu W, Alkhouri R, et al. Structural changes in the gut microbiome of constipated patients. Physiol Genomics. 2014;46(18):679-686. doi:10.1152/physiolgenomics.00082.2014
Katakami N, Harada T, Murata T, et al. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2017;35(34):3859-3866. doi:10.1200/JCO.2017.73.0853
Inoue A, Iwase S, Nozawa K, et al. The safety and effectiveness of naldemedine for opioid-induced constipation in patients with advanced cancer in real-world palliative care settings: a multicenter prospective observational study. Support Care Cancer. 2024;32(8):513. doi:10.1007/s00520-024-08716-8
Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332-2343. doi:10.1056/NEJMoa0707377
Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008;35(5):458-468. doi:10.1016/j.jpainsymman.2007.12.005
Rauck R, Slatkin NE, Stambler N, Harper JR, Israel RJ. Subcutaneous methylnaltrexone for opioid-induced constipation in advanced-illness patients with or without active cancer. Pain Pract. 2020;20(4):378-387. doi:10.1111/papr.12862
Siemens W, Gaertner J, Becker G. Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes. Ther Clin Risk Manag. 2016;12:401-412. doi:10.2147/TCRM.S80749
